06:21 AM EDT, 06/23/2025 (MT Newswires) -- Novo Nordisk A/S ( NVO ) announced on Sunday that its Phase 3 REDEFINE 1 trial, evaluating CagriSema for weight loss in overweight or obese adults without diabetes, met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss compared to placebo.

The study showed that treatment with CagriSema resulted in a mean weight loss of 22.7% at 68 weeks, compared to 2.3% in the placebo group, assuming all patients adhered to treatment.

Moreover, select confirmatory secondary endpoints showed that 40.4% of those receiving CagriSema achieved a body weight reduction of at least 25% if all participants adhered to treatment.

Results from REDEFINE 2, another Phase 3 study evaluating CagriSema in adults with obesity and type 2 diabetes, showed an estimated mean decrease in body weight from baseline to week 68 of 15.7% with CagriSema versus 3.1% with placebo, assuming all participants adhered to treatment.

The company's shares were down 3% in recent Monday premarket activity.